Japan’s pharmaceutical market is the third largest in the world, following the United States and China. Credit: Vitalii Stock via Shutterstock.com.
Japan’s pharmaceutical industry – the world’s third largest by market value after the United States and China – has long been associated with methodical development cycles and rigorous technical validation. But the sector is undergoing a gradual yet increasingly visible shift in how it evaluates external partners and drug development programmes.
Across therapeutics, particularly complex modalities such as peptides, the defining constraint is moving from scientific feasibility to execution speed. Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Find out more
